ClinicalTrials.gg

Program

amezosvatein

A development code. Also written as “CRV 101”.

Its studies are mostly in Herpes Zoster, led by Eli Lilly.

Furthest: phase 1, since Jan 24, 20191 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly10 open or runningphase 1since Jan 24, 2019Jan 24, 2019none ahead
  • Named in Eli Lilly’s own pipeline as Amezosvatein, phase 2, as of Oct 29, 2026 (source).

Also a collaborator on its studies: GC Biopharma.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 24, 2019First study: phase 1 study in Herpes ZosterFirst studyNCT03820414 · 90 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03820414Herpes Zoster · United States1CompletedApr 4, 202090

How it is read

Names in the registry

  • “CRV 101”, 1 entry

Codes read as this program: CRV101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.